Clearstead Advisors’s AYTU BioPharma AYTU Stock Holding History

Clearstead Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-71	Closed	-$2K	–	1372
2021 Q4	$2K	Hold	71	–	–	﹤0.01%	1094
2021 Q3	$4K	Hold	71	–	–	﹤0.01%	1043
2021 Q2	$7K	Hold	71	–	–	﹤0.01%	833
2021 Q1	$11K	Hold	71	–	–	﹤0.01%	768
2020 Q4	$8K	Hold	71	–	–	﹤0.01%	743
2020 Q3	$17K	Hold	71	–	–	﹤0.01%	603
2020 Q2	$20K	Buy	+71	New	+$21.5K	﹤0.01%	525

Other funds holding AYTU

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Clearstead Advisors's AYTU Position: Q1 2022 in Review

Clearstead Advisors sold out of AYTU BioPharma (AYTU) in Q1 2022, closing a stake of 71 shares — an estimated $2K sold.

Clearstead Advisors first reported a position in AYTU in Q2 2020 and held it in 7 quarters. The position peaked at $20K in Q2 2020. 32 funds tracked by Wall St. Rank hold AYTU as of Q1 2022.

Clearstead Advisors reported no remaining AYTU BioPharma position as of Q1 2022 after selling out during the quarter.
Clearstead Advisors sold 71 AYTU BioPharma shares in Q1 2022, an estimated $2K.
Clearstead Advisors first reported a position in AYTU BioPharma in Q2 2020 and held it in 7 quarters.
Clearstead Advisors's AYTU BioPharma position peaked at $20K in Q2 2020.
32 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2022.

Based on Clearstead Advisors's 13F filing for Q1 2022, filed 4 May 2022.